SCHEMBL384229

SCHEMBL384229

O[C@H]1CC[C@H](N(Cc2ccccc2)Cc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 1/20 0.55
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 1/20 0.44
SLC18A3 Q16572 1/20 0.44
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
GRIN2B Q13224 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 2/20 0.43
OPRM1 P35372 2/20 0.41
OPRD1 P41143 2/20 0.41
OPRK1 P41145 2/20 0.41
ACKR3 P25106 1/20 0.40
G6PC1 P35575 1/20 0.40
CCR5 P51681 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384230 1.00 YTHDC1 (0.55) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL23329339 1.00 YTHDC1 (0.55) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL17685339 0.92 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL3376962 0.90 YTHDC1 (0.58) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL25111999 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL23329113 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL25341885 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL29182197 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL29182199 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL13017781 0.84 SLC6A2 (0.53) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617799-B2 Pyrazolopyrimidinone compounds Orphagen Pharmaceuticals, Inc. (US) 2026-05-05 US disclosed
EP-4724430-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE Flagship Pioneering Innovations VI, LLC (US) 2026-04-15 EP disclosed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
EP-4676931-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BioSplice Therapeutics, Inc. (US) 2026-01-14 EP disclosed
EP-4674415-A2 AZAQUINOLINES AS INHIBITORS OF CD38 Boehringer Ingelheim International GmbH (DE) 2026-01-07 EP disclosed
US-12514858-B2 CD38 inhibitors Astellas Engineered Small Molecules US, Incorporated (US) 2026-01-06 US disclosed
US-20250340558-A1 CRYSTALLINE SUBSTITUTED CYCLOHEXYL PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND AND THERAPEUTIC USES THEREOF BIAL R&D INVEST S A (PT) 2025-11-06 US disclosed
EP-4171567-B1 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORP (US) 2025-09-03 EP disclosed
EP-4171568-B1 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORP (US) 2025-08-27 EP disclosed
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-08-26 US disclosed
EP-0779888-A1 PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM Dr. Karl Thomae GmbH (DE) 1997-06-25 EP disclosed
US-5612335-A ANTICOAGULANTS; COMBATING/PREVENTING DISEASES WHERE CELL AGGREGATES OCCUR OR CELL-MATRIX INTERACTIONS PLAY A PART KARL THOMAE GMBH (DE) 1997-03-18 US disclosed
US-5591769-A PYRROLIDINE DERIVATIVES; ANTICOAGULANTS KARL THOMAE GMBH (DE) 1997-01-07 US disclosed
US-5541343-A ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS KARL THOMAE GMBH (DE) 1996-07-30 US disclosed
US-5519036-A IMIDAZOLIDINONES, ANTICOAGULANTS, CELL AGGREGATION PREVENTION KARL THOMAE GMBH (DE) 1996-05-21 US disclosed
WO-1996007657-A1 PYRIMIDO[5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM DR. KARL THOMAE GMBH (DE) 1996-03-14 WO disclosed
EP-0638553-A1 Carboxylic acid amides having a terminal carboxylic acid group as aggregation inhibiting drugs Dr. Karl Thomae GmbH (DE) 1995-02-15 EP disclosed
EP-0612741-A1 Cyclic derivatives, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1994-08-31 EP disclosed
EP-0587134-A2 Cyclic urea derivatives, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1994-03-16 EP disclosed
EP-0483667-A2 Cyclic imino derivatives, process for their preparation and drugs containing them Dr. Karl Thomae GmbH (DE) 1992-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 CD38, PARP12, ENTPD2 YTHDC1 2143/4885SLC6A2 3435/4885SLC6A4 4749/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B YTHDC1 1951/4885SLC6A2 1400/4885SLC6A4 3445/4885
US-20250340558-A1 CRYSTALLINE SUBSTITUTED CYCLOHEXYL PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND AND THERAPEUTIC USES THEREOF GBA1, GAA, PARK7 YTHDC1 972/4885SLC6A2 3732/4885SLC6A4 4311/4885
US-12617799-B2 Pyrazolopyrimidinone compounds CYP2B6, CBR1, CYP2D6 YTHDC1 3462/4885SLC6A2 3238/4885SLC6A4 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.